CL2011002315A1 - Compuestos derivados de pirimidindiona fusionados con pirrol, moduladores de receptores trpa1; composicion farmaceutica; y uso para tratar el dolor cronico, dolor reumatoide artritico o dolor osteoartritico. - Google Patents

Compuestos derivados de pirimidindiona fusionados con pirrol, moduladores de receptores trpa1; composicion farmaceutica; y uso para tratar el dolor cronico, dolor reumatoide artritico o dolor osteoartritico.

Info

Publication number
CL2011002315A1
CL2011002315A1 CL2011002315A CL2011002315A CL2011002315A1 CL 2011002315 A1 CL2011002315 A1 CL 2011002315A1 CL 2011002315 A CL2011002315 A CL 2011002315A CL 2011002315 A CL2011002315 A CL 2011002315A CL 2011002315 A1 CL2011002315 A1 CL 2011002315A1
Authority
CL
Chile
Prior art keywords
pain
pyrimidinedione
fused
pharmaceutical composition
pyrrole
Prior art date
Application number
CL2011002315A
Other languages
English (en)
Spanish (es)
Inventor
Sukeerthi Kumar
Sachin Sundarlal Chaudhri
Abraham Thomas
Nisha Parag Patil
Ashok Bhausaheb Kadam
Vishal Go Deshmukh
Original Assignee
Glenmark Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa
Publication of CL2011002315A1 publication Critical patent/CL2011002315A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2011002315A 2009-03-23 2011-09-20 Compuestos derivados de pirimidindiona fusionados con pirrol, moduladores de receptores trpa1; composicion farmaceutica; y uso para tratar el dolor cronico, dolor reumatoide artritico o dolor osteoartritico. CL2011002315A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN665MU2009 2009-03-23
IN2211MU2009 2009-09-23
IN2212MU2009 2009-09-23
IN2892MU2009 2009-12-15
IN2891MU2009 2009-12-15

Publications (1)

Publication Number Publication Date
CL2011002315A1 true CL2011002315A1 (es) 2012-04-09

Family

ID=42780198

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2011002315A CL2011002315A1 (es) 2009-03-23 2011-09-20 Compuestos derivados de pirimidindiona fusionados con pirrol, moduladores de receptores trpa1; composicion farmaceutica; y uso para tratar el dolor cronico, dolor reumatoide artritico o dolor osteoartritico.
CL2014001447A CL2014001447A1 (es) 2009-03-23 2014-06-02 Compuestos derivados de pirimidindiona fusionada con pirazol, moduladores de receptores trpa1; composicion farmaceutica y uso para el dolor cronico, dolor reumatoide artritico o dolor osteoartritico (div. sol. 2315-11)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2014001447A CL2014001447A1 (es) 2009-03-23 2014-06-02 Compuestos derivados de pirimidindiona fusionada con pirazol, moduladores de receptores trpa1; composicion farmaceutica y uso para el dolor cronico, dolor reumatoide artritico o dolor osteoartritico (div. sol. 2315-11)

Country Status (23)

Country Link
US (1) US9000159B2 (enExample)
EP (2) EP2411393B1 (enExample)
JP (1) JP5657638B2 (enExample)
KR (1) KR20110132575A (enExample)
CN (1) CN102361873B (enExample)
AP (1) AP3280A (enExample)
AU (1) AU2010227245B2 (enExample)
BR (1) BRPI1013559A2 (enExample)
CA (1) CA2756518A1 (enExample)
CL (2) CL2011002315A1 (enExample)
DK (1) DK2411393T3 (enExample)
EA (1) EA023857B1 (enExample)
ES (2) ES2456515T3 (enExample)
IL (1) IL215178A (enExample)
MX (1) MX2011009824A (enExample)
PE (1) PE20120774A1 (enExample)
PL (1) PL2411393T3 (enExample)
PT (1) PT2411393E (enExample)
SG (1) SG174402A1 (enExample)
SI (1) SI2411393T1 (enExample)
UA (1) UA108069C2 (enExample)
WO (1) WO2010109287A1 (enExample)
ZA (1) ZA201107648B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11655245B2 (en) 2018-03-19 2023-05-23 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008019357A2 (en) 2006-08-07 2008-02-14 Ironwood Pharmaceuticals, Inc. Indole compounds
EA023857B1 (ru) 2009-03-23 2016-07-29 Гленмарк Фармасеутикалс С.А. Сочлененные производные пиримидиндионов в качестве модуляторов trpa1
JP5694560B2 (ja) 2010-12-20 2015-04-01 グレンマーク ファーマシューティカルズ， エセ．アー． Ｔｒｐａ１アンタゴニストとしての２−アミノ−４−アリールチアゾール化合物
AR084433A1 (es) 2010-12-22 2013-05-15 Ironwood Pharmaceuticals Inc Inhibidores de la faah y composiciones farmaceuticas que los contienen
EP2520566A1 (en) 2011-05-06 2012-11-07 Orion Corporation New Pharmaceutical Compounds
CN103826637A (zh) 2011-06-13 2014-05-28 格兰马克药品股份有限公司 使用trpa1拮抗剂治疗呼吸疾患
US20140107113A1 (en) 2011-06-22 2014-04-17 Glenmark Pharmaceuticals S.A. Pharmaceutical composition comprising a trpa1 antagonist and a beta-2 agonist
WO2012176105A1 (en) 2011-06-22 2012-12-27 Glenmark Pharmaceuticals Sa Pharmaceutical composition comprising a trpa1 antagonist and a leukotriene receptor antagonist
WO2013014597A1 (en) 2011-07-25 2013-01-31 Glenmark Pharmaceuticals Sa Pharmaceutical composition comprising a trpa1 antagonist and a steroid
CN103265543A (zh) 2011-08-09 2013-08-28 丘比斯特药物股份有限公司 抑制瞬时受体电位离子通道trpa1
EP2787991A1 (en) 2011-12-05 2014-10-15 Glenmark Pharmaceuticals S.A. Pharmaceutical composition comprising a trpa1 antagonist and an anticholinergic agent
JP6182072B2 (ja) 2012-01-17 2017-08-16 Ｅａファーマ株式会社 複素環アミド誘導体及びそれを含有する医薬
NZ701721A (en) 2012-06-08 2016-03-31 Glenmark Pharmaceuticals Sa Amides of 2-amino-4-arylthiazole compounds and their salts
NZ706989A (en) 2012-10-01 2018-07-27 Orion Corp N-prop-2-ynyl carboxamide derivatives and their use as trpa1 antagonists
US9394308B2 (en) 2013-01-18 2016-07-19 Merck Sharp & Dohme Corp. Inhibiting the transient receptor potential A1 ion channel
US9532988B2 (en) 2013-10-15 2017-01-03 Glenmark Pharmaceuticals S.A. Pharmaceutical composition comprising a TRPA1 antagonist and an analgesic agent
CN104884457B (zh) * 2013-10-30 2016-12-07 上海恒瑞医药有限公司 吡唑并嘧啶酮类或吡咯并三嗪酮类衍生物、其制备方法及其在医药上的应用
CN103755705B (zh) * 2014-02-17 2017-02-15 上海佰特因医药科技有限公司 一种天然产物四甲基尿酸的全合成方法
JP6667092B2 (ja) * 2014-08-11 2020-03-18 ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ， ＬＬＣ ピロロ［３，２−ｄ］ピリミジン−２，４（３Ｈ，５Ｈ）−ジオン誘導体
WO2016042501A1 (en) 2014-09-16 2016-03-24 Glenmark Pharmaceuticals S.A. Trpa1 antagonist for the treatment of pain associated to diabetic neuropathic pain
CN105001170A (zh) * 2015-07-13 2015-10-28 佛山市赛维斯医药科技有限公司 末端腈基取代的三氮唑亚砜类化合物、其制备方法及其用途
WO2017060488A1 (en) 2015-10-09 2017-04-13 Almirall, S.A. New trpa1 antagonists
WO2017064068A1 (en) 2015-10-14 2017-04-20 Almirall, S.A. New trpa1 antagonists
WO2019020102A1 (zh) * 2017-07-28 2019-01-31 江苏恒瑞医药股份有限公司 一种嘧啶酮并杂芳基类衍生物的制备方法及其中间体
CN109422749B (zh) * 2017-08-21 2023-01-24 重庆医药工业研究院有限责任公司 一种抑制单羧酸转运蛋白的嘧啶二酮衍生物
CN108558836A (zh) * 2018-05-14 2018-09-21 东南大学 一类具有双重作用机制的dpp-4抑制剂及其用途
WO2023096915A1 (en) * 2021-11-24 2023-06-01 Slap Pharmaceuticals Llc Multicyclic compounds
MX2024009581A (es) * 2022-02-03 2024-08-13 De Shaw Res Llc Compuestos de uracilo n3-sustituidos como inhibidores de trpa1.
JP2025510646A (ja) * 2022-03-14 2025-04-15 スラップ ファーマシューティカルズ エルエルシー 多環式化合物
CN114656472B (zh) * 2022-04-27 2023-07-04 成都施贝康生物医药科技有限公司 吡唑并嘧啶类化合物、异构体或盐及其制备方法和用途
CN114656473B (zh) * 2022-04-27 2023-09-29 成都施贝康生物医药科技有限公司 吡咯并嘧啶类化合物、异构体或盐及其制备方法和用途
CN114656480B (zh) * 2022-04-27 2024-01-26 成都施贝康生物医药科技有限公司 噻吩并嘧啶类化合物、异构体或盐及其制备方法和用途
CN118373832B (zh) * 2023-01-20 2025-01-28 深圳晶蛋生物医药科技有限公司 大环类化合物、其药物组合物及其应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2248231A1 (de) 1972-10-02 1974-04-11 Basf Ag 3-aminoisothiazolo eckige klammer auf 3,4-d eckige klammer zu pyrimidine
SE9701398D0 (sv) * 1997-04-15 1997-04-15 Astra Pharma Prod Novel compounds
ES2193839B1 (es) 2001-06-22 2005-02-16 Almirall Prodesfarma, S.A. Nuevos derivados de 6-fenildihidropirrolpirimidindiona.
AU2003253165A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
AU2003290066A1 (en) 2002-12-18 2004-07-09 Novartis Ag Anktm1, a cold-activated trp-like channel expressed in nociceptive neurons
JP2007522214A (ja) * 2004-02-11 2007-08-09 スミスクライン・ビーチャム・コーポレイション Ｐｔｈアゴニスト
US20070196866A1 (en) 2004-03-13 2007-08-23 Irm Llc Modulators of ion channel trpa1
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
JPWO2006083005A1 (ja) 2005-02-03 2008-06-26 武田薬品工業株式会社 縮合ピリミジン誘導体およびその用途
US20060291462A1 (en) * 2005-06-28 2006-12-28 Utstarcom, Inc. Method and apparatus using multiple application cards to comprise multiple logical network entities
WO2007073505A2 (en) * 2005-12-22 2007-06-28 Hydra Biosciences, Inc. Trpa1 inhibitors for treating pain
TW200800997A (en) 2006-03-22 2008-01-01 Astrazeneca Ab Chemical compounds
AR065081A1 (es) 2007-01-29 2009-05-13 Xenon Pharmaceuticals Inc Compuestos de quinazolinona y pirimidona fusionados y composicion farmaceutica
EP2170309B1 (en) 2007-06-22 2016-10-26 Hydra Biosciences, Inc. 2,6-dioxo,-2,3-dihydro-1h-purine compounds useful for treating disorders related to the activity of the trpa1 channel
WO2009158719A2 (en) * 2008-06-27 2009-12-30 Hydra Biosciences, Inc. Methods and compositions for treating disorders
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
SG184766A1 (en) 2009-03-23 2012-10-30 Glenmark Pharmaceuticals Sa Isothiazolo-pyrimidinedione derivatives as trpa1 modulators
SI2411395T1 (sl) 2009-03-23 2013-07-31 Glenmark Pharmaceuticals S.A. Furopirimidindionski derivati kot TRPA1 modulatorji
EA023857B1 (ru) 2009-03-23 2016-07-29 Гленмарк Фармасеутикалс С.А. Сочлененные производные пиримидиндионов в качестве модуляторов trpa1
AR076332A1 (es) 2009-04-21 2011-06-01 Boehringer Ingelheim Int Derivados heterociclicos de 5-alquinil-piridinas, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento y/o prevencion del cancer, procesos inflamatorios, autoinmunes, y/o infecciones.
MX2011012903A (es) 2009-06-18 2012-02-01 Basf Se Mezclas fungicidas.
AR078522A1 (es) 2009-10-15 2011-11-16 Lilly Co Eli Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
EP2488524B1 (en) 2009-10-15 2013-07-03 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine compounds
EP2311844A1 (en) 2009-10-15 2011-04-20 Interquim, S.A. Silyl polymeric benzoic acid ester compounds, uses, and compositions thereof
US8404461B2 (en) 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
PL2483255T3 (pl) 2010-07-13 2014-03-31 Novartis Ag Pochodne oksazyny i ich zastosowanie w leczeniu zaburzeń neurologicznych

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11655245B2 (en) 2018-03-19 2023-05-23 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors
US12202824B2 (en) 2018-03-19 2025-01-21 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors

Also Published As

Publication number Publication date
PE20120774A1 (es) 2012-06-27
EP2708538B1 (en) 2015-08-12
HK1166075A1 (en) 2012-10-19
IL215178A0 (en) 2011-12-29
US9000159B2 (en) 2015-04-07
HK1194742A1 (en) 2014-10-24
JP5657638B2 (ja) 2015-01-21
DK2411393T3 (da) 2014-04-07
EA023857B1 (ru) 2016-07-29
ES2551085T3 (es) 2015-11-16
SI2411393T1 (sl) 2014-03-31
CN102361873A (zh) 2012-02-22
WO2010109287A1 (en) 2010-09-30
AU2010227245A2 (en) 2011-10-27
CL2014001447A1 (es) 2014-10-17
BRPI1013559A2 (pt) 2016-04-12
JP2012521401A (ja) 2012-09-13
EP2411393A1 (en) 2012-02-01
PL2411393T3 (pl) 2014-06-30
EP2708538A1 (en) 2014-03-19
ZA201107648B (en) 2012-07-25
AP3280A (en) 2015-05-31
PT2411393E (pt) 2014-02-21
EP2411393B1 (en) 2014-01-22
AP2011005887A0 (en) 2011-10-31
AU2010227245A1 (en) 2011-09-22
IL215178A (en) 2015-01-29
EP2411393A4 (en) 2012-08-01
SG174402A1 (en) 2011-10-28
AU2010227245B2 (en) 2015-09-10
UA108069C2 (uk) 2015-03-25
KR20110132575A (ko) 2011-12-08
MX2011009824A (es) 2012-01-25
ES2456515T3 (es) 2014-04-22
CA2756518A1 (en) 2010-09-30
EA201190143A1 (ru) 2012-04-30
US20140128603A1 (en) 2014-05-08
CN102361873B (zh) 2014-07-09

Similar Documents

Publication Publication Date Title
CL2011002315A1 (es) Compuestos derivados de pirimidindiona fusionados con pirrol, moduladores de receptores trpa1; composicion farmaceutica; y uso para tratar el dolor cronico, dolor reumatoide artritico o dolor osteoartritico.
CL2008000825A1 (es) Compuestos heterociclicos derivados de quinolincarboxamidas utiles como antagonistas de p2x7; su metodo de preparacion; la composicion farmaceutica que lo contiene; el emtodo de preparacion de la composicion; y el uso de los mismos para preparar medicamentos utiles en artritis reumatoide.
CL2011000087A1 (es) Compuestos derivados de heteroarilo sustituido, inhibidores de los receptores dgat1; composicion farmaceutica; y su uso para tratar la diabetes tipo ll y obesidad.
EA201370066A1 (ru) Модуляторы эстрогеновых рецепторов и их применение
BRPI0917315A2 (pt) anticorpo, composicao farmaceutico, e, uso de uma composicao farmaceutica
CL2011002877A1 (es) Anticuerpo que reconoce el dominio fnd1 del receptor ax1; composicion farmaceutica que lo comprende; y su uso para tratar cancer.
CL2007003726A1 (es) Anticuerpos anti-receptor del factor del crecimiento similar a la insulina i (igf-ir); composicion farmaceutica que lo contiene; y su uso para tratar el cancer.
CL2013001107A1 (es) Polipeptido derivado de la il-2 con actividad agonista; proteina de fusion que lo comprende; composicion farmaceutica que lo comprende; y su uso para tratar cancer y enfermedades infecciosas cronicas.
CL2008000467A1 (es) Compuestos derivados de 2-aminopirimidina, moduladores del receptor histamina h4; su procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno inflamatorio seleccionado de alegia, asma
CL2007003226A1 (es) Compuestos derivados de piridinona; composicion farmaceutica; y uso para tratar el cancer.
SV2006002167A (es) Moduladores del receptor de progesterona que comprenden derivados de pirrol- oxindol y sus usos ref. am101791
CL2013001783A1 (es) Analogos de glucagon que presentan actividad potente en receptor de gip; dimero o multidimero; conjugado; composicion farmaceutica que los comprende; y sus usos en tratar diabetes u obesidad.
BRPI0908131A2 (pt) Uso de vídeo com disparadores para identificação de conteúdo anterativo
CL2008000094A1 (es) Compuestos derivados de pteridina; composicion farmaceutica que comprende a dichos compuestos; y su uso para aumentar la vasodilatacion.
CL2011000501A1 (es) Composición farmacéutica que comprende un agonista de gpr119 en combinación con un inhibidor de dpp-4 seleccionado de un grupo definido; uso para prevenir y/o tratar enfermedades metabólicas, como resistencia insulinica, diabetes, sindrome metabolico, obesidad, hiperlipidemia, osteoporosis, entre otras.
BRPI1005322A2 (pt) anticorpo, composição farmacêutica e uso de pelo menos um anticorpo
BRPI1007018A2 (pt) composto, composição farmacêutica, e , uso de um composto.
CL2007002316A1 (es) Compuestos derivados de pirimidina, inhibidores de pi3k; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en enfermedades proliferativas como cancer.
BRPI0817462A2 (pt) Uso de um aditivo em uma composição de combustível diesel.
CL2013000459A1 (es) Anticuerpo aislado o fragmento que se enlaza a un estado inactivo de un receptor her; composicion farmaceutica que lo comprende; uso del anticuerpo para tratar cancer.
CL2008002041A1 (es) Compuestos derivados de piperidina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar ansiedad.
CL2011001464A1 (es) Compuestos derivados de purina, agonistas del receptor cb2; composicion farmaceutica que los comprende; y uso del compuesto para tratar el dolor osteoartritico.
BRPI1008906A2 (pt) composto, composição farmacêutica, e, uso de um composto.
CL2013002053A1 (es) Compuestos derivados de heterociclicos, antagonistas del receptor de glucagon; composicion farmaceutica que lo comprende y su uso en el tratamiento de diabetes y enfermedades metabolicas. pct
CL2012000921A1 (es) Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes.